Lumanity is proud to be taking part at ISPOR 2023, the leading global health economics and outcomes research (HEOR) conference. ISPOR connects global HEOR leaders, policy makers, regulators, researchers, academics, payers, patients, and patient groups under one roof to network and discuss and debate the latest trends in healthcare.
This year it’s all about keeping you powered-up. Lumanity are sponsoring the charging lounge and our experts will be sparking discussion and debate in workshops and poster presentations – you can find full details of these sessions below.
Our Experts
From discussing your upcoming project’s needs or to find out about the many exciting opportunities to join us and level-up your career at Lumanity, our team are happy to connect with you.
If you are interested in scheduling a meeting with one of our experts attending ISPOR 2023, please don’t hesitate to reach out using the link below.
Ron Akehurst, Executive Chair, HEOR
Chris Evans, President, Patient-Centered Outcomes
Jonathan Kowalski, Executive Vice President, Head of US HEOR
Dan Simpson,
Senior Vice President, EU RWE Strategy
Peter Pancione, Vice President, US Real World Evidence Partner Engagement
David Robinson, Senior Vice President, Commercial Strategy & Operations
Jeff Lee,
Vice President, US Value Strategy & Services
Alexis Kuchins, Vice President, HEOR Global Commercial Partnerships
Yang Meng,
Senior Director, US Head of Health Economics Analysis
Linda Murphy,
Senior Director, HEOR
Martha Gauthier, Senior Director, Patient-Centered Outcomes
Brandon Foster, Director, Psychometrics & Statistics, Patient-Centered Outcomes
Nathan Johnson, Director, Patient-Centered Outcomes
Shayna Egan, Director, Patient-Centered Outcomes
TingTing Qu,
Senior Health Economist, HEOR
Workshops
Monday, 8 May | 10:15 – 11:15am (EDT)
Ron Akehurst, Karen Facey, Shahid Hanif, Linda Murphy.
Lumanity’s Ron Akehurst and Linda Murphy take part in this discussion which aims to present a partial solution to HTA agencies’ reluctance to use real world evidence and data (RWE/D), particularly on relative effectiveness, to reach reimbursement decisions.
Posters
Monday, 8 May – Poster Session 1 | 12:15 – 13:15pm (EDT)
Fluctuation in Treatment Initiation: Increasing the Accuracy of Modeling Patient Entry in Budget Impact Analyses
Neves C, Bappoo Y, Bjerke A, Bruette R.
Impact in Health Outcomes of Anti-PD(L)1 Inhibitors to Treat Early-Stage Cancers in Belgium
Aguiar-Ibáñez R, Neves C, Mantaian T, Abreu A, Sönmez D, Sillah A, Aktan G.
Association of Time of Loss of Ambulation with Severity of Respiratory Symptoms in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (NMDMD)
Tulinius M, Zhang R, Lee B, Madin-Warburton M, Werner C, Tomazos I.
Monday, 8 May – Poster Session 2 | 5:45 – 6:45pm (EDT)
Budget Impact Analysis of Pembrolizumab Plus Enfortumab Vedotin As First-Line Treatment of Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma in USA
Lai Y, Guo H, Arku D, Meng Y, Li H.
Development and Validation of Patient-Reported Outcome Measures for Platysma Prominence
Garcia J, Whyte J, Gauthier M, Foster B, Foley C, Patel V.
Economic Burden of Cystic Fibrosis in the United States: A Systematic Review
Verma R, Aggarwal T, Ahuja A.
Impact of Signs and Symptoms of Chronic Refractory Gout on Patient Health-Related Quality of Life
Oladapo A, Pillinger M, Kragh N, Johnson N, Yousefian C, Brooks D, Sharp H, Strand V.
Use of Real-World Evidence to Support Direct Oral Anti-Coagulant Reimbursement and Implementation in Atrial Fibrillation. a Comparison of Experiences in Three Markets
Murphy L, De Pouvourville G, Sola Morales O, Cunningham D, Akehurst R.
Tuesday, 9 May – Poster Session 4 | 5:45 – 6:45pm (EDT)
Assessing Patient Preference for Verbal Descriptor Scales
Johnson N, Egan S, Gauthier M, Witherspoon B, Foster B, Evans C.
Development of the Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale (ABBA-CAS)
Yi BA, Yousefian C, Gauthier M, Salter J, Bloomfield D, Glasspool J.
Menopausal Women at Work: The Measured and Unmeasured Impact of Symptoms on Productivity
Filonenko A, Woods M, Haberland C, Engelhardt A, Bolling KR, Gerlinger C, Seitz C, Pietsch GA, Malacan J, Taneja A, Harchand S, Jindal S, Smith M.
Methods of Incorporating Changes in Drug Price over Time into Health Economic Evaluations: A Targeted Literature Review
Puls M, Mehboob S, Horscroft J, Kearns B, Malcolm B, Kalirai S, Borrill J.
Wednesday, 10 May – Poster Session 5 | 09:00 – 10:00am (EDT)
Patient-Driven Development of Meaningful Change Estimates in Chronic Pain
Egan S, Gauthier M, Witherspoon B, Foster B, Johnson N, Evans C.
Evaluating the Psychometric Properties of a Questionnaire Designed to Assess Headache Characteristics and Management Among United States Student Pharmacists
Agu U, Arku D, Axon D.